SEC Company Response from RedHill Biopharma Ltd. (RDHL) (CIK 0001553846) (RDHL) — Jul 31, 2018
RedHill Biopharma Ltd. (RDHL) (CIK 0001553846)
Date: July 31, 2018 · CIK: 0001553846 · Accession: 0001171843-18-005551
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226278
Letter
RedHill Biopharma Ltd.
21 Ha'arba'a St.
Tel Aviv, 64739, Israel
July 31, 2018
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
RE: RedHill Biopharma Ltd.
Registration Statement on Form F-3
Filed July 23, 2018
File No. 333-226278
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, RedHill Biopharma Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-mentioned Registration Statement on Form F-3 (the “Registration Statement”) to 4:00 p.m., Eastern Time on July 31, 2018, or as soon thereafter as practicable.
Should any member of the staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
RedHill Biopharma Ltd.
Show Raw Text
CORRESP
1
filename1.htm
RedHill Biopharma Ltd.
21 Ha'arba'a St.
Tel Aviv, 64739, Israel
July 31, 2018
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
RE:
RedHill Biopharma Ltd.
Registration Statement on Form F-3
Filed July 23, 2018
File No. 333-226278
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 of the Rules
and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933,
as amended, RedHill Biopharma Ltd. (the “Company”) hereby requests acceleration of the effective date of the
above-mentioned Registration Statement on Form F-3 (the “Registration Statement”) to 4:00 p.m., Eastern Time
on July 31, 2018, or as soon thereafter as practicable.
Should any member of the staff of the U.S. Securities
and Exchange Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone,
LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
RedHill Biopharma Ltd.
By:
/s/ Dror Ben- Asher
Dror Ben-Asher
Chief Executive Officer